Press Releases Oragenics, Inc.

Equities

Market Closed - Nyse Other stock markets 21:00:00 16/05/2024 BST			5-day change	1st Jan Change
1.64 ^USD	+0.12%		+18.84%	-70.85%

08:03pm	Sector Update: Health Care Stocks Ease Thursday Afternoon	MT
06:53pm	Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise	MT

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial	01:01pm	AQ
Oragenics: Q1 Earnings Snapshot	05-15	AQ
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia	05-07	AQ
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards	04-19	BU
Oragenics, Inc. Files 10K and Provides Company Update	04-01	BU
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	03-18	BU
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	03-05	BU
Oragenics Announces Closing of Public Offering	03-04	AQ
Oragenics Announces Closing of Public Offering	03-01	BU
Oragenics Announces Pricing of Public Offering	02-28	BU
Oragenics Announces Proposed Public Offering	02-27	BU
Oragenics, Inc. Announces Leadership Transition	02-12	BU
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement	02-07	BU
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion	02-05	BU
Oragenics Announces Termination of At-The-Market Offering Program	01-23	BU
Oragenics Completes Acquisition of Odyssey Health's Neurological Assets	01-02	AQ
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets	01-02	BU
Oragenics: Q3 Earnings Snapshot	11-10	AQ
Oragenics Issues Update to Shareholders	11-02	BU
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors	18/10/23	BU

No results for this search